Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
$81,000 |
 |
AmgenAMGN |
$160,000 |
 |
BridgeBio PharmaBBIO |
$40,000 |
 |
TuHURA BiosciencesHURA |
$83,000 |
 |
Alnylam PharmaceuticalsALNY |
-$33,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julia Letlow | Feb 12, 2026 | Buy | $1K - $15K |
| Rob Bresnahan | May 15, 2025 | Buy | $1K - $15K |
| Byron Donalds | Apr 10, 2025 | Sell | $1K - $15K |
| Rob Bresnahan | Feb 25, 2025 | Sell | $1K - $15K |
| Julie Johnson | Feb 12, 2025 | Sell | $1K - $15K |
| Josh Gottheimer | Jan 24, 2025 | Sell | $1K - $15K |
| Julie Johnson | Jan 15, 2025 | Buy | $1K - $15K |
| Josh Gottheimer | Nov 29, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Nov 19, 2024 | Sell | $1K - $15K |
| Jonathan Jackson | Nov 13, 2024 | Sell | $15K - $50K |
| Jonathan Jackson | Nov 1, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Oct 23, 2024 | Sell | $1K - $15K |
| Greg Landsman | Oct 15, 2024 | Sell | $1K - $15K |
| Ro Khanna | Sep 9, 2024 | Buy | $1K - $15K |
FAQ - Congress Trading
Julia Letlow purchased Regeneron shares most recently on February 12, 2026.
Ro Khanna has bought the most REGN stock in the last 2 years, with an estimated value of $8,000.
Jonathan Jackson has sold the most REGN stock in the last 2 years, with an estimated value of $41,000.
The net value of trades by US politicians for Regeneron in the last 2 years is negative, amounting to -$73,000. This suggests that US politicians do not believe in the success of the company for various reasons.
Over the last 2 years, insider transactions for Regeneron have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
